GANX 241220 2.00P (GANX241220P2000) Stock Options, News & Quotes

US OptionsDetailed Quotes

GANX241220P2000

Watchlist

0.00
0.000.00%

15min DelayNot Open Nov 22 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Maxim Group Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $5
Moomoo NewsNov 20 13:32 ET · Ratings
Chardan Capital Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $6
Moomoo NewsNov 19 03:36 ET · Ratings
Gain Therapeutics Advances Parkinson's Therapy Development
TipRanksNov 18 22:57 ET
Gain Therapeutics Receives Buy Rating as GT-02287 Shows Promise for GBA1 Parkinson's Disease
TipRanksNov 18 20:05 ET · Ratings
Gain Therapeutics | 8-K: Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update
SECNov 14 17:15 ET
Gain Therapeutics Reports Q3 EPS (17c), Consensus (21c)
TipRanksNov 14 16:21 ET

Comments

Stock_Drift

Nov 14 18:01

After Hours Ticks. 7:00pm

$Mercurity Fintech (MFH.US)$ $Freightos (CRGO.US)$ $1847 Holdings (EFSH.US)$ $MediciNova (MNOV.US)$ $Despegar.com (DESP.US)$ $NextPlat (NXPL.US)$ $Legacy Education (LGCY.US)$ $Gain Therapeutics (GANX.US)$ $Red Cat Holdings (RCAT.US)$ $Siyata Mobile (SYTA.US)$ $Innovation Beverage Group (IBG.US)$ $Greenidge Generation (GREE.US)$ $The Arena Group (AREN.US)$
📊⚡️📊

Stock_Drift

Oct 30 17:49

After Hours Ticks. 6:48pm

$Gain Therapeutics (GANX.US)$ $Orion Group (ORN.US)$ $Nextracker (NXT.US)$ $Alphatec (ATEC.US)$ $Remitly Global (RELY.US)$ $1847 Holdings (EFSH.US)$ $Carvana (CVNA.US)$ $Junee (JUNE.US)$ $Tenon Medical (TNON.US)$ $Aditxt (ADTX.US)$ $CPS Technologies (CPSH.US)$ $Root Inc (ROOT.US)$
📊⚡️📊

Jaguar8

Oct 7 06:01

NEWS

$Gain Therapeutics (GANX.US)$
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024
Gain Therapeutics presented new preclinical data for GT-02287 at the Society for Neuroscience 2024 conference. The data demonstrates disease-modifying activity in both GBA-1 and idiopathic Parkinson's disease models. Key findings include:
1. Persistent rescue of motor and cognitive function after GT-02287 discontinuation
2. Improved mitochondrial function and neuroprotection in GBA1-Parkins...

Trytosaveabit

Sep 30 06:37

Update

$Gain Therapeutics (GANX.US)$ Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers
Gain Therapeutics, Inc. Mon, Sep 30, 2024, 7:00 AM 7 min read
Gain Therapeutics, Inc.
GT-02287 Increases Peripheral GCase Activity
GT-02287 Demonstrates CNS Exposure

Stock_Drift

Sep 26 06:19

$Gain Therapeutics (GANX.US)$